This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
LEXINGTON, Mass., June 18, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced that the Company will present at the JMP Securities Healthcare Conference at 3:30 p.m. ET on June 25, 2014, in New York City.
Dr. Ali Fattaey, President and Chief Executive Officer, will provide an overview of Curis' proprietary cancer programs including its dual histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) inhibitor, CUDC-907, and its antagonist of inhibitor of apoptosis (IAP) proteins, CUDC-427. Dr. Fattaey will also provide an overview of Curis' partnered programs including Erivedge® (vismodegib), a hedgehog pathway inhibitor developed under collaboration with Genentech and Roche that is the only approved medicine for patients with advanced basal cell carcinoma, and Debio 0932, an HSP90 inhibitor that is in clinical development by Curis' collaborator Debiopharm.
A corresponding webcast of the presentation can be accessed by visiting:
The webcast will be archived shortly after the live event and available for 30 days following the conference. In addition, it will be available for 30 days on the Investor Relations section of the Curis website at
About Curis, Inc.
Curis is an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers. Curis is seeking to further the development of its pipeline of proprietary targeted cancer drug candidates, including CUDC-907, a dual HDAC and PI3K inhibitor, and CUDC-427, a small molecule antagonist of IAP proteins. Curis is also engaged in a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are developing and commercializing Erivedge®, the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma. Curis partner Debiopharm is studying HSP90 inhibitor Debio 0932 in patients with advanced lung cancer. For more information, visit Curis' website at
CONTACT: Mani Mohindru, Ph.D.
Vice President, Corporate Strategy and Investor Relations
Michael P. Gray
Chief Business and Financial Officer